128 related articles for article (PubMed ID: 2668325)
21. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
Davies PH; Stewart SE; Lancranjan L; Sheppard MC; Stewart PM
Clin Endocrinol (Oxf); 1998 Mar; 48(3):311-6. PubMed ID: 9578821
[TBL] [Abstract][Full Text] [Related]
22. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
23. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
24. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects.
Halse J; Harris AG; Kvistborg A; Kjartansson O; Hanssen E; Smiseth O; Djøsland O; Hass G; Jervell J
J Clin Endocrinol Metab; 1990 May; 70(5):1254-61. PubMed ID: 2186055
[TBL] [Abstract][Full Text] [Related]
25. The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly.
Comi RJ; Gorden P
J Clin Endocrinol Metab; 1987 Jan; 64(1):37-42. PubMed ID: 2878009
[TBL] [Abstract][Full Text] [Related]
26. [A multicenter clinical trial of SMS 201-995 (octreotide acetate) in acromegaly and gigantism].
Shimatsu A; Imura H; Irie M; Nakagawa S; Goto Y; Shimizu N; Takeda R; Kato Y; Saito S; Ibayashi H
Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):640-52. PubMed ID: 2684694
[TBL] [Abstract][Full Text] [Related]
27. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995).
Caron P; Cogne M; Gusthiot-Joudet B; Wakim S; Catus F; Bayard F
Eur J Endocrinol; 1995 Mar; 132(3):320-5. PubMed ID: 7889181
[TBL] [Abstract][Full Text] [Related]
28. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
[TBL] [Abstract][Full Text] [Related]
29. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
Ezzat S; Redelmeier DA; Gnehm M; Harris AG
J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
[TBL] [Abstract][Full Text] [Related]
30. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
32. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
Riedel M; Günther T; von zur Mühlen A; Brabant G
Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
[TBL] [Abstract][Full Text] [Related]
34. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.
Lamberts SW; Oosterom R; Neufeld M; del Pozo E
J Clin Endocrinol Metab; 1985 Jun; 60(6):1161-5. PubMed ID: 2860119
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly.
Wagenaar AH; Harris AG; van der Lely AJ; Lamberts SW
Acta Endocrinol (Copenh); 1991 Dec; 125(6):637-42. PubMed ID: 1789059
[TBL] [Abstract][Full Text] [Related]
36. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
37. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.
Lindsay JR; McConnell EM; Hunter SJ; McCance DR; Sheridan B; Atkinson AB
Pituitary; 2004; 7(3):139-144. PubMed ID: 16328564
[TBL] [Abstract][Full Text] [Related]
38. Acute and long-term effects of SMS 201-995 in acromegaly.
Lamberts SW; del Pozo E
Scand J Gastroenterol Suppl; 1986; 119():141-8. PubMed ID: 2876498
[TBL] [Abstract][Full Text] [Related]
39. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly.
Lorcy Y; Dejager S; Chanson P;
Pituitary; 2000 Nov; 3(3):193-7. PubMed ID: 11383486
[TBL] [Abstract][Full Text] [Related]
40. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.
Moller DE; Moses AC; Jones K; Thorner MO; Vance ML
J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]